Comments on ICER’s Draft Evidence Report on Plinabulin and Trilaciclib Chemotherapy-Induced Neutropenia
ICER has announced its intent to issue a final evidence report in this review without first holding a public hearing, a highly unusual decision.
Patients Snubbed by Health Economists
Even after vowing to expand patients’ engagement in its process, the nation’s most active health technology assessment organization has shut them out.
